FDA Investigator James P Mcreavey

James P Mcreavey has inspections in 11 countries as of 29 Sep 2023. James P Mcreavey has collaborated with a combinined 3100 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
Last Inspection Date:
29 Sep 2023
Investigator Role:
FDA Investigator
Redica ID:
United Kingdom of Great Britain and Northern Ireland, Germany, Italy, United States of America, France, Canada, China, India, Netherlands, Taiwan
A Williams, Adree N Anderson, Alan E Mehl, Alan P Kurtzberg, Alberto A Viciedo, Alicia M Mozzachio, Alysia C Alger, Anastasia M Shields, Andrew A Hoopes, Anna Lazar, Arsen Karapetyan, Arthur S Williams, Jr, Avery J Dennis, Azza Talaat, Bonnie E Pierson, Brenda C Hamilton, Brent M Dehaan, Brian R Yaun, Brian S Keefer, Brooke K Higgins, Candace S Tucker, CDR Sean T Creighton, Charanjeet Jassal, Charisse K Green, Charles I Ann, Chilton L Ng, Clifford F Long, Cody J Alley, Courtney R Bratina, Cynthia A Harris, MD, RN, Danial S Hutchison, Darrah, David M Beltran, Diana K Krepel, Dina K West, Dipesh K Shah, Donna Ltartaglino Besone, Dr. Robert C Horan, MD, Dr. S Nar Ali, PhD, Dustin K Hampton, Dwight D Ferguson, Emmanuel A Dimaano, Jr, Eric C Fox, Eric C Nielsen, Eric M Mueller, PharmD, Eric M Padgett, Eric T Huebler, Evelyn Taha, Felix J Marrero, Francis A Guidry, Frank J Marciniak, Frederick Razzaghi, Gam S Zamil, Gerardo Z Vazquez, German Rivera, Gregson A Joseph, Gwyn G Dickinson, Harperd, Ismael Oera Lv, Ismael Olvera, IV, Jacob G Lutz, James D Planchon, Javier O Vega, Jeffrey B Moody, Jennifer S Ness, Jenny Aagila Sefen, Jensel L Guadalupe, Jessica E Hensley, Jimmie L Weigand, Johnson, Johnsont, Jonathan R Campos, Joohi Castelvetere, Jorge L Guadalupe, Jose Alopez Rubet, Jose R Hernandez, Joseph R Lambert, Juanita Banuelos, Karen M Montgomery (KMM), Katherine Szestypalow, Kellia N Hicks, Kelvin Cheung, Kent C Faul, Kevin P Foley, Kevin P Regan, Kimberly Lewandowski Walker, Kristin M Abaonza, Larry K Austin, Latorie S Jones, Lawrence Harmon, Jr, LCDR Debra Emerson, LCDR Matthew J Morrison, Linda K Cline, Linda R Kuchenthal, Linhart, Lisa L Flores, Lori A Carr, Lucas B Leake, Maribeth G Niesen, Marie A Fadden, Marion D Wimberly, Jr, Marisol Faberlle, Mark E Parmon, Marybet Lopez, Matthew B Casale, Matthew J Sienko, Meisha R Sampson, Meisha Waters, Melanie W Pishnery, Merril E Racke, Merril Racke, PhD, Michael A Charles, Michael L Casner, Michael R Goga, Michael S Araneta, Michele L Obert, Michele Perry Williams, Michelle J Glembin, Minerva Rogers, Monica E Caphart, Mra Davism, Mra Mcculloughj, Nadine J Nanko, Nadine Nanko Johnson, Nasir Ali, PhD, Nicholas L Paulin, Nicole C Mayfield, Norman K Starks, Paraluman S Leonin, Paul L Figarole, Jr, Perry H Gambrell, Rachel C Harrington, Rafael Padilla, Richard H Penta, Rita K Kabaso, Robert J Ham, Rochelle L Cross, Rodney D Combs, Rosanna M Goodrich, Roy Baby, Russell J Glapion, Samuel K Gibbons, Jr, Sandra A Boyd, Sarah E Mcmullen, Seema S Singh, Sharon K Thoma, PharmD, Shelby N Marler, Shirley J Berryman, Simone E Pitts, Sneha S Patel, State Agency, Stephen C Smith, Stephen D Eich, Stephen R Souza, Steven M Weinman, Steven P Allen, Steven P Donald, Susanna E Ford, Analyst, Susant Hadman, Syed N Ali, Terri L Dodds, Terry C Kimball, Thai T Duong, Thomas J Arista, Thuy T Nguyen, LCDR, Tiara Nbrown Crosen, Tina M Pawlowski, Torrey M Ward, Tracey L Harris, Truong Xuan Nguyen (Andy), Veronica Fuentes, MS, Vlada Matusovsky, Walsworth, Warren J Lopicka, Wen Ning Chan (Sally), Yumi J Hiramine, Zachary A Bogorad

James P Mcreavey's Documents

Publish Date Document Type Title
July, 2004 FDA 483 Delasco, LLC - Form 483, 2004-07-16
October, 2002 FDA 483 Response Sichuan Long March Pharmaceutical Co. Ltd. - Form 483R, 2002-11-20
September, 2002 FDA 483 Delasco, LLC - Form 483, 2002-09-09
April, 2002 FDA 483 Mesa Laboratories Inc - Form 483, 2002-04-22
February, 2002 FDA 483 Response Bausch & Lomb/Technolas Gmbh - Form 483R, 2002-04-03
April, 2005 FDA 483 Telex Communications Inc - Form 483, 2005-04-01
October, 2002 EIR Nanjing Pharmaceutical Factory Co., Ltd. - EIR, 2002-10-17
October, 2002 FDA 483 Response Shanghai Fourth Pharmaceuticals, Ltd. - Form 483R, 2002-12-06
October, 2002 FDA 483 Nanjing Pharmaceutical Factory Co., Ltd. - Form 483, 2002-10-17
October, 2002 EIR Sichuan Long March Pharmaceutical Co. Ltd. - EIR, 2002-10-25
October, 2000 FDA 483 Primus Sterilizer Co., Inc. - Form 483, 2000-10-06
January, 2004 FDA 483 EPM Packaging Inc - Form 483, 2004-01-09
October, 2001 EIR GSK Consumer Health, Inc. - EIR, 2001-10-18
February, 2002 FDA 483 Technolas GmbH - Form 483, 2002-02-14
May, 2004 FDA 483 Penner Mfg Inc - Form 483, 2004-05-14
September, 2003 FDA 483 Response Merck Sharp & Dohme BV - Form 483R, 2003-10-06
October, 2002 EIR Shanghai Fourth Pharmaceuticals, Ltd. - EIR, 2002-10-31
May, 2000 FDA 483 LAB-Interlink, Inc. - Form 483, 2000-05-11
April, 2002 FDA 483 Response Mesa Laboratories Inc - Form 483R, 2002-09-04
October, 2001 FDA 483 GSK Consumer Health, Inc. - Form 483, 2001-10-18
August, 2002 EIR Prince Agri Products, Inc. - EIR, 2002-08-09
May, 2000 EIR LAB-InterLink Inc - EIR, 2000-05-11
October, 2002 FDA 483 Sichuan Long March Pharmaceutical Co. Ltd. - Form 483, 2002-10-25
February, 2002 EIR Bausch & Lomb/Technolas Gmbh - EIR, 2002-02-14
September, 2003 FDA 483 Merck Sharp & Dohme BV - Form 483, 2003-09-25
October, 2002 FDA 483 Shanghai Fourth Pharmaceuticals, Ltd. - Form 483, 2002-10-31
September, 2003 EIR Merck Sharp & Dohme BV - EIR, 2003-09-25
April, 2002 EIR Mesa Laboratories Inc - EIR, 2002-04-22

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

Talk to sales to access our investigator profiles


Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more